Newcelx Ltd (NCEL)

$3.28 +0.09 (2.82%)
Market Cap 18.43M
Revenue (ttm) 0.00
Net Income (ttm) -8.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.05
Volume 13,800
Avg Vol 21,944
Day's Range N/A - N/A
Shares Out 5.78M
Stochastic %K 25%
Beta 0.94
Analysts Strong Buy
Price Target N/A

Company Profile

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 44 512 21 50
Fax: 41 44 512 21 51
Website: newcelx.com
Address:
Hohstrasse 1, Kloten, Switzerland
FrostyOrbit
FrostyOrbit Aug. 29 at 7:22 PM
$NCEL Has a small market cap ($18M) and only 2.68M shares in the float, creating potential for large moves on catalysts/volume…
0 · Reply
FrostyOrbit
FrostyOrbit Aug. 29 at 7:20 PM
$NCEL Raised $1.4M at $4.033/share a 20% premium to the prior close bullish validation from investors.,…
0 · Reply
DonCorleone77
DonCorleone77 Aug. 21 at 12:47 AM
$OSIS $AVAH $NCEL AFTER-HOURS MOVERS: Currently Higher After Earnings: - Ross Stores (ROST) up 8.7% Currently Also Higher: - Spotify Technology (SPOT) up 0.9% after boosting share buyback Currently Lower After Earnings: - Flux Power (FLUX) down 23.8% - Flowers Foods (FLO) down 4.5% - OSI Systems (OSIS) down 13.4% Currently Also Lower: - Aveanna Healthcare (AVAH) down 8.6% after equity offering - NewcelX Ltd. (NCEL) down 5.0% after selling stock for holders.
0 · Reply
ShutupGhaleon
ShutupGhaleon Aug. 10 at 6:43 PM
$NCEL This has to be my favorite stock. It drops every single day, there's very little volume and management is more secretive than the CIA. I'm thinking it could hit $4 by 2046.
0 · Reply
focafoca99
focafoca99 Jul. 31 at 1:47 PM
$NCEL notified pricing of a $1.4 million equity financing at a 20% premium.
0 · Reply
focafoca99
focafoca99 Jul. 15 at 5:40 PM
$NCEL recently secured a Brazilian patent for its NCEL-101 Type 1 diabetes therapy, expanding its IP portfolio.
0 · Reply
kshonstocks
kshonstocks Jul. 9 at 3:32 PM
$NCEL on scans has the higher high and is hod here
0 · Reply
focafoca99
focafoca99 Jul. 8 at 1:51 PM
$NCEL recruited Dr. Camillo Ricordi to its Scientific Advisory Board.
0 · Reply
macec
macec Jul. 6 at 5:01 PM
$NCEL what’s going on here?
0 · Reply
Robert345
Robert345 Jul. 1 at 1:07 AM
$NCEL was this the stock dropping after the news today ???
0 · Reply
Latest News on NCEL
NewcelX registers to sell 694K common shares for holders

2026-08-20T20:20:33.000Z - 11 days ago

NewcelX registers to sell 694K common shares for holders

NewcelX announces pricing of $1.4M equity financing

2026-07-31T13:21:28.000Z - 4 weeks ago

NewcelX announces pricing of $1.4M equity financing

NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing

Jul 31, 2026, 9:00 AM EDT - 4 weeks ago

NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing

NewcelX announces Brazil patent for cell selection, enrichment technology

2026-07-15T13:15:48.000Z - 6 weeks ago

NewcelX announces Brazil patent for cell selection, enrichment technology

NewcelX initiated with a Buy at Laidlaw

2026-07-13T09:00:13.000Z - 7 weeks ago

NewcelX initiated with a Buy at Laidlaw

NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board

Jul 8, 2026, 9:15 AM EDT - 7 weeks ago

NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board

NewcelX completes Type B Pre-IND meeting with FDA for NCEL-101

2026-07-01T13:35:15.000Z - 2 months ago

NewcelX completes Type B Pre-IND meeting with FDA for NCEL-101

ELDN

NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes

Jul 1, 2026, 9:30 AM EDT - 2 months ago

NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes

NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform

Jun 15, 2026, 8:30 AM EDT - 2 months ago

NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform

NewcelX submits NCEL-101 pre-investigational new drug briefing package to FDA

2026-05-27T14:42:14.000Z - 3 months ago

NewcelX submits NCEL-101 pre-investigational new drug briefing package to FDA

ELDN

NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes

May 27, 2026, 7:55 AM EDT - 3 months ago

NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes

NewcelX files to sell 2.26M common shares for holders

2026-05-11T22:55:46.000Z - 4 months ago

NewcelX files to sell 2.26M common shares for holders

NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

Apr 30, 2026, 8:15 AM EDT - 4 months ago

NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

NewcelX announces release of updated presentation on Type 1 Diabetes program

2026-04-20T11:43:42.000Z - 4 months ago

NewcelX announces release of updated presentation on Type 1 Diabetes program

ELDN

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

Apr 20, 2026, 7:37 AM EDT - 4 months ago

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing

Apr 1, 2026, 7:21 AM EDT - 5 months ago

NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing

NewcelX announces research agreement with Eledon Pharmaceuticals

2026-03-09T11:12:39.000Z - 6 months ago

NewcelX announces research agreement with Eledon Pharmaceuticals

ELDN

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

Mar 9, 2026, 7:00 AM EDT - 6 months ago

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

ELDN

NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy

Feb 12, 2026, 7:00 AM EST - 7 months ago

NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy

NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences

Jan 29, 2026, 7:00 AM EST - 7 months ago

NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences

NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression

Jan 12, 2026, 7:00 AM EST - 8 months ago

NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression

NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board

Jan 5, 2026, 7:00 AM EST - 8 months ago

NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board

NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China

Dec 11, 2025, 7:00 AM EST - 9 months ago

NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China

NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute

Nov 17, 2025, 7:00 AM EST - 10 months ago

NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute

NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board

Nov 6, 2025, 7:00 AM EST - 10 months ago

NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board

NewcelX CEO Issues Letter to Shareholders

Nov 4, 2025, 7:00 AM EST - 10 months ago

NewcelX CEO Issues Letter to Shareholders

NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.

Nov 3, 2025, 8:25 AM EST - 10 months ago

NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.

NLSP

FrostyOrbit
FrostyOrbit Aug. 29 at 7:22 PM
$NCEL Has a small market cap ($18M) and only 2.68M shares in the float, creating potential for large moves on catalysts/volume…
0 · Reply
FrostyOrbit
FrostyOrbit Aug. 29 at 7:20 PM
$NCEL Raised $1.4M at $4.033/share a 20% premium to the prior close bullish validation from investors.,…
0 · Reply
DonCorleone77
DonCorleone77 Aug. 21 at 12:47 AM
$OSIS $AVAH $NCEL AFTER-HOURS MOVERS: Currently Higher After Earnings: - Ross Stores (ROST) up 8.7% Currently Also Higher: - Spotify Technology (SPOT) up 0.9% after boosting share buyback Currently Lower After Earnings: - Flux Power (FLUX) down 23.8% - Flowers Foods (FLO) down 4.5% - OSI Systems (OSIS) down 13.4% Currently Also Lower: - Aveanna Healthcare (AVAH) down 8.6% after equity offering - NewcelX Ltd. (NCEL) down 5.0% after selling stock for holders.
0 · Reply
ShutupGhaleon
ShutupGhaleon Aug. 10 at 6:43 PM
$NCEL This has to be my favorite stock. It drops every single day, there's very little volume and management is more secretive than the CIA. I'm thinking it could hit $4 by 2046.
0 · Reply
focafoca99
focafoca99 Jul. 31 at 1:47 PM
$NCEL notified pricing of a $1.4 million equity financing at a 20% premium.
0 · Reply
focafoca99
focafoca99 Jul. 15 at 5:40 PM
$NCEL recently secured a Brazilian patent for its NCEL-101 Type 1 diabetes therapy, expanding its IP portfolio.
0 · Reply
kshonstocks
kshonstocks Jul. 9 at 3:32 PM
$NCEL on scans has the higher high and is hod here
0 · Reply
focafoca99
focafoca99 Jul. 8 at 1:51 PM
$NCEL recruited Dr. Camillo Ricordi to its Scientific Advisory Board.
0 · Reply
macec
macec Jul. 6 at 5:01 PM
$NCEL what’s going on here?
0 · Reply
Robert345
Robert345 Jul. 1 at 1:07 AM
$NCEL was this the stock dropping after the news today ???
0 · Reply
Flowjob
Flowjob Jun. 29 at 3:11 PM
$NCEL FDA meeting this week, positive feedback news would send this to double digits 1.9M float.
1 · Reply
yoni30
yoni30 Jun. 16 at 1:33 PM
$NCEL What a boring stock, waiting too long for real developments
0 · Reply
Evilmarine
Evilmarine Jun. 16 at 11:22 AM
$NCEL ouch 🤕
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 12 at 3:27 AM
$NCEL
0 · Reply
focafoca99
focafoca99 Jun. 5 at 8:42 PM
$NCEL conducts its annual shareholders' meeting on June 30, 2026.
0 · Reply
KuddyGage
KuddyGage May. 27 at 5:27 PM
$NCEL did news come out Dumping
0 · Reply
DannyDff
DannyDff May. 27 at 2:28 PM
$NCEL anybody here?
0 · Reply
Travelling
Travelling May. 27 at 2:02 PM
$VSEE I sold this in October at 2.29, also watching $RKTO, $NCEL, $FIRY holding $CADL
0 · Reply
DannyDff
DannyDff May. 27 at 1:07 PM
$NCEL is this dead today
0 · Reply